POM

GUANGZHOU, China, July 15, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its ongoing efforts to strengthen its healthcare data ecosystem, by leveraging real-world data ("RWD"), artificial intelligence ("AI"), wearable technologies, remote patient monitoring ("RPM") capabilities and physician resources to enable more personalized, predictive and continuous healthcare management. As digital transformation accelerates across healthcare systems worldwide, RWD is emerging as a critical foundation for AI-enabled healthcare innovation.

GUANGZHOU, China, July 13, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on July 10, 2026, the Company received a letter (the "Compliance Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). As a result, the matter has been closed.

GUANGZHOU, China, July 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its continued efforts in building an AI-powered chronic disease management ecosystem. The Company is integrating artificial intelligence ("AI"), remote patient monitoring ("RPM"), wearable technologies and real-world healthcare data to evolve toward a predictive, continuous and personalized healthcare service provider.

GUANGZHOU, China, July 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced a strategic upgrade, officially positioning the Company as a foundational infrastructure provider for predictive healthcare data and services. The strategic upgrade reflects the Company's continued evolution from a traditional online healthcare platform toward an artificial intelligence ("AI")-enabled healthcare infrastructure provider.

GUANGZHOU, China, June 17, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced that, as previously announced on May 28, 2026, the ratio change of its American depositary shares (the "ADSs") to Class A ordinary shares from the current ratio of one (1) ADS representing one-sixth (1/6) Class A ordinary share to a new ratio of one (1) ADS representing three (3) Class A ordinary shares (the "ADS Ratio Change") will become effective on June 22, 2026, U.S. Eastern Time (the "Effective Date"). For the Company's ADS holders, the ADS Ratio Change will have the same effect as a one-for-eighteen reverse ADS split.

GUANGZHOU, China, May 28, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") to its Class A ordinary shares (the "ADS Ratio Change"), from the current ratio of one (1) ADS representing one-sixth (1/6) Class A ordinary share to a new ratio of one (1) ADS representing three (3) Class A ordinary shares. For the Company's ADS holders, the ADS Ratio Change will have the same effect as a one-for-eighteen reverse ADS split.

GUANGZHOU, China, May 14, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its financial results for the fiscal year ended December 31, 2025. Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "Fiscal year 2025 marked a year of solid revenue expansion and continued execution of our growth strategy.

New York, New York--(Newsfile Corp. - April 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PomDoctor Ltd. (NASDAQ: POM) between October 9, 2025 and December 11, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.

NEW YORK, April 13, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PomDoctor Ltd. (NASDAQ: POM) between October 9, 2025 and December 11, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pomdoctor To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Pomdoctor between October 9, 2025 and December 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.